Elsa Borghi

Elsa Borghi is an expert in drug and class III medical device development in oncology. She brings to Diaccurate to 25 years of experience that led her from the hospital and academia to Big Pharma and Biotech companies. As Global Clinical Development Director at Sanofi, she was in charge of early oncology developments and the evaluation of innovative technologies. She oversaw the clinical development that led to the registration in metastatic prostate adenocarcinoma of Taxotere (docetaxel), in the EU and US markets. As Chief Medical Officer of Nanobiotix, she led the structuration of the programs and teams supporting the development of Hensify® (NBTXR3). She was instrumental in its successful EU registration in adult soft tissue sarcoma.
 
Elsa is a trained physician from the University of Paris, she also holds a Master’s degree in Life Sciences, Early development and Somatic models from the Pierre and Marie Curie University in Paris.